Introduction: Active Ingredient Sameness in ANDA is demonstrated by proving that the generic drug’s API is identical to the Reference […]
How to Demonstrate Active Ingredient Sameness in an ANDA Submission Read More »
Introduction: Why Long Acting Injectables Market Trends Are Shifting the Generic Pharma Calculus The Long Acting Injectables Market Trends observed
Future of Long-Acting Injectables & Generic Opportunities Read More »
Choosing the right Contract Research Organization (CRO) for complex injectables is a strategic decision that goes far beyond basic outsourcing.
Selecting the Right CRO for Complex Generic Injectables Read More »
Introduction: Why Lupron Depot Development Failures Persist Lupron Depot Development Failures continue to shape the reality of long-acting injectable (LAI)
Common Failures in Leuprolide Depot Generic Development Read More »
Introduction: Sameness Evaluation in ANDA is the scientific and regulatory process of proving that a generic drug’s active ingredient is
Sameness Evaluation in ANDA: Complete Guide for Active Ingredient Assessment Read More »
Introduction: The Liraglutide Sameness Study is essential to prove that a generic liraglutide product is molecularly identical to the reference listed drug
Introduction Long Acting Injectables Characterization focuses on understanding microstructure, release mechanisms, and polymer-drug interactions using advanced analytical techniques. This approach
Advanced Characterization Techniques for Long Acting Injectables Products Read More »
Introduction: Why Risk Allocation Matters More Than Risk Avoidance in Generic Development In complex generic pharmaceutical development, risk cannot be
Risk-Sharing Collaboration Models in Complex Generic Development Read More »
Introduction: A Semaglutide Sameness Study is a comprehensive analytical comparison between a proposed generic semaglutide and the reference product. The goal is
Introduction: GLP-1 Peptide Mapping Regulatory Requirements are central to demonstrating biosimilarity and structural integrity in generic drug development. Regulatory authorities
Regulatory Expectations for Peptide Mapping in GLP-1 Generic Drug Development Read More »
